ACELYRIN (SLRN)

SLRN was delisted on the 21st of May, 2025.

• Market cap: $229M
• Sector: Healthcare
• Industry: Biotechnology

About: Acelyrin Inc is a late-stage clinical biopharmaceutical company. The clinical biopharma segment researches and develops treatments for diseases with pathology related to excess activation of the immune system. It is focused on providing patients with life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of transformative medicines.

Employees: 83